MEDICAL PROFESSIONALS

Disease State

The impact of Afib

 

Afib has a significant impact on the quality of life of patients, in addition to its clinical impact on stroke. Afib increases the risk of stroke 2- to 17-fold and is responsible for up to 20% of all strokes (ref. 1, 4-6).


 

The clinical factors for increased risk of thromboembolic events in Afib patients are easily identified and include congestive heart failure (CHF), history of hypertension, and previous arterial thromboembolism (ref. 7). Likewise, the risk of CHF remains high after diagnosis of Afib. However, in addition to the clinical impact, Afib places considerable burden on the healthcare system and is predicted to significantly impact healthcare costs, with hospitalization costs being the major cost driver in treatment of Afib (ref. 8).

©Johnson & Johnson Medical NV/SA, 2010. Last update on:03 Feb 2012 This site is published by Johnson & Johnson Medical NV/SA, which is solely responsible for its contents. This section of the website is intended for visitors from the European Economic Area (EEA), excluding France. The EEA includes the 25 EU member states and Norway, Iceland, and Liechtenstein. Capitalized product names are trademarks of Biosense Webster.